Showing 1 - 20 results of 20,759 for search '"PD-L1"', query time: 1.30s Refine Results
1
Tubeimoside-1 induces TFEB-dependent lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting mTOR

Authors: Xiaojia Liu, Mingxiao Yin, Jingwen Dong, Genxiang Mao, Wenjian Min, Zean Kuang, Peng Yang, Lu Liu, Na Zhang, Hongbin Deng

Source: Acta Pharmaceutica Sinica B, Vol 11, Iss 10, Pp 3134-3149 (2021)
Acta Pharmaceutica Sinica. B

Subject Terms: PD-L1, Immune checkpoint blockade, Transcription factor EB, Lysosome, mTOR, Therapeutics. Pharmacology, RM1-950, General Pharmacology, Toxicology and Pharmaceutics, Original Article, Baf, bafilomycin A1, CETSA, cellular thermal shift assay, CHX, cycloheximide, CQ, chloroquine, 4EBP1, eIF4E-binding protein 1, IB, immunoblotting, ICB, immune checkpoint blockade, IHC, immunohistochemistry, LLC, Lewis lung carcinoma, MDSCs, myeloid-derived suppressor cells, mTOR, mammalian target of rapamycin, NAG, β-N-acetylglucosaminidase, NSCLC, non-small cell lung cancer, PD-1, programmed cell death-1, PD-L1, programmed cell death ligand- 1, p70S6K, phosphorylation of p70 S6 kinase, qRT-PCR, quantitative real-time polymerase chain reaction, SPR, surface plasmon resonance, TBM-1, tubeimoside-1, TFEB, nuclear transcriptional factor EB, TILs, tumor-infiltrating lymphocytes, Tregs, regulatory T-lymphocytes

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71d344df92d314f733377ab3c9584020
http://www.sciencedirect.com/science/article/pii/S2211383521001118

2
PD-L1 Protein Expression and Gene Amplification Correlate with the Clinicopathological Characteristics and Prognosis of Lung Squamous Cell Carcinoma

Authors: Chen, Zhenwen, Zhao, Ning, Wang, Qi, Xi, Yanfeng, Tian, Xiaoai, Wu, Huiwen, Xu, Yirong

Source: Cancer Management and Research, Vol Volume 13, Pp 6365-6375 (2021)
Cancer Management and Research

Subject Terms: pd-l1 protein expression, pd-l1 gene amplification, lung squamous cell carcinoma, prognosis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, Oncology, Original Research, Cancer Management and Research

File Description: text/html

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6956ab7fc580e89f8deda6ab3d14c38
https://www.dovepress.com/pd-l1-protein-expression-and-gene-amplification-correlate-with-the-cli-peer-reviewed-fulltext-article-CMAR

3
Academic Journal
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)

Authors: Kowanetz, Marcin, Zou, Wei, Gettinger, Scott N., Koeppen, Hartmut, Kockx, Mark, Schmid, Peter, Kadel, Edward E., Wistuba, Ignacio, Chaft, Jamie, Rizvi, Naiyer A., Spigel, David R., Spira, Alexander, Hirsch, Fred R., Cohen, Victor, Smith, Dustin, Boyd, Zach, Miley, Natasha, Flynn, Susan, Leveque, Vincent, Shames, David S., Ballinger, Marcus, Mocci, Simonetta, Shankar, Geetha, Funke, Roel, Hampton, Garret, Sandler, Alan, Amler, Lukas, Mellman, Ira, Chen, Daniel S., Hegde, Priti S.

Source: Proceedings of the National Academy of Sciences of the United States of America. 115(43):E10119-E10126

Access URL: https://www.jstor.org/stable/26532386

4
Academic Journal
Adjuvant effect of the novel TLR1/TLR2 agonist Diprovocim synergizes with anti–PD-L1 to eliminate melanoma in mice

Authors: Wang, Ying, Su, Lijing, Morin, Matthew D., Jones, Brian T., Mifune, Yuto, Shi, Hexin, Wang, Kuan-wen, Zhan, Xiaoming, Liu, Aijie, Wang, Jianhui, Li, Xiaohong, Tang, Miao, Ludwig, Sara, Hildebrand, Sara, Zhou, Kejin, Siegwart, Daniel J., Moresco, Eva Marie Y., Zhang, Hong, Boger, Dale L., Beutler, Bruce

Source: Proceedings of the National Academy of Sciences of the United States of America. 115(37):E8698-E8706

Access URL: https://www.jstor.org/stable/26531326

6
Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy

Authors: Jie Chen, Huapan Fang, Yingying Hu, Jiayan Wu, Sijia Zhang, Yuanji Feng, Lin Lin, Huayu Tian, Xuesi Chen

Source: Bioactive Materials, Vol 7, Iss, Pp 167-180 (2022)
Bioactive Materials

Subject Terms: Gene delivery, PD-L1 blockade, Targeted vaccine, Nanovaccines, Tumor immunotherapy, Materials of engineering and construction. Mechanics of materials, TA401-492, Biology (General), QH301-705.5, Article, Biomedical Engineering, Biomaterials, Biotechnology

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cb6085578e244424a7736a7e8c20c87
http://www.sciencedirect.com/science/article/pii/S2452199X21002565

9
Local adenoviral delivery of soluble CD200R-Ig enhances antitumor immunity by inhibiting CD200-β-catenin-driven M2 macrophage

Authors: Seung-Phil Shin, A-Ra Goh, Ji-Min Ju, Hyeon-Gu Kang, Seok-Jun Kim, Jong-Kwang Kim, Eun-Jung Park, Yong-Soo Bae, Kyungho Choi, Yuh-Seog Jung, Sang-Jin Lee

Source: Molecular Therapy: Oncolytics, Vol 23, Iss, Pp 138-150 (2021)
Molecular Therapy Oncolytics

Subject Terms: CD200, β-catenin, NF-κB, PD-L1, M-CSF, M2-like macrophage, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, Pharmacology (medical), Cancer Research, Oncology, Molecular Medicine, Original Article

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4924c4707b0e9268f2f5e2ae9413939
http://www.sciencedirect.com/science/article/pii/S2372770521001285

10
Comparative analysis of IL-1β blood serum concentration, neutrophil-to-lymphocytes ratio in peripheral blood, and the levels of PD-L1 expression in malignant tissues of the patients with various solid tumors

Authors: R. V. Orlova, N. V. Zhukova, A. M. Malkova, E. A. Kaledina, A. R. Gubal, V. V. Sharoiko

Source: Medicinskaâ Immunologiâ, Vol 23, Iss 5, Pp 1105-1114 (2021)

Subject Terms: il-1β, neutrophil-to-lymphocyte ratio, pd-l1, correlation, solid tumors, immune therapy, Immunologic diseases. Allergy, RC581-607

Access URL: https://explore.openaire.eu/search/publication?articleId=doajarticles::5fdef77002767950c9d08fd5d5648ee3
https://www.mimmun.ru/mimmun/article/view/2197

11
Programmed Death-Ligand 1 Expression in Breast Cancer Patients: Clinicopathological Associations from a Single-Institution Study

Authors: Ayoub,Nehad M, Fares,Mona, Marji,Raya, Al Bashir,Samir M, Yaghan,Rami J

Source: Breast Cancer : Targets and Therapy, Vol Volume 13, Pp 603-615 (2021)

Subject Terms: breast cancer, pd-l1, immunohistochemistry, clinicopathologic, prognosis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, Targets and Therapy [Breast Cancer]

File Description: text/html

Access URL: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::19530508c9418899c7eebcc00113c84e
https://www.dovepress.com/programmed-death-ligand-1-expression-in-breast-cancer-patients-clinico-peer-reviewed-fulltext-article-BCTT

12
Prognostic implication of PD‐L1 polymorphisms in non‐small cell lung cancer treated with radiotherapy

Authors: Min Kyu Kang, Shin Yup Lee, Jin Eun Choi, Sook Kyung Do, Moon‐June Cho, Jun‐Sang Kim, Jae Yong Park

Source: Cancer Medicine, Vol 10, Iss 22, Pp 8071-8078 (2021)

Subject Terms: non‐small cell lung cancer, PD‐L1, polymorphisms, radiotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, Cancer Research, Radiology Nuclear Medicine and imaging, Oncology

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e58648fea63de89b983b6a10348bd4f3
https://doaj.org/article/9fb4f3f87b164d22987a18702f7ec04d

PDF Full Text
14
RHBDF2 gene functions are correlated to facilitated renal clear cell carcinoma progression

Authors: Wang, Lei, Liu, Xiu-Xiu, Yang, Yu-Meng, Wang, Yan, Song, Yuan-Yuan, Gao, Shan, Li, Lu-Yuan, Zhang, Zhi-Song

Source: Cancer Cell International, Vol 21, Iss 1, Pp 1-18 (2021)
Cancer Cell International

Subject Terms: Kidney renal clear cell carcinoma, Rhomboids, RHBDF2, Cancer prognosis, PD-L1, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, Cytology, QH573-671, Primary Research

Access URL: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::4d65c449a2119a4ec79e3664e0d8292b
https://doaj.org/article/df4bf013587f4ca28b22dcfb633345d9

HTML Full Text     PDF Full Text
15
Prognostic Significance of Serum PD-L1 Level in Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Combination Cytotoxic Chemotherapy

Authors: Rong Fu, Chuan-Qing Jing, Xiu-Rong Li, Zhao-Feng Tan, Hui-Jie Li

Source: Cancer Management and Research
Cancer Management and Research, Vol Volume 13, Pp 4935-4946 (2021)

Subject Terms: Original Research, esophageal squamous cell carcinoma, PD-L1, soluble PD-L1, prognosis, clinical outcome, chemotherapy, Cancer Management and Research, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, Oncology

File Description: text/html

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14038927ef116690bbcb90038436d64f
http://europepmc.org/articles/PMC8232859

16
IFNγ/PD-L1 Signaling Improves the Responsiveness of Anti-PD-1 Therapy in Colorectal Cancer: An in vitro Study

Authors: Yuan,Wenli, Deng,Deyao, Li,Hanyu, Hu,Xinghui, Shang,Xueqin, Hou,Xia, Jiang,Hongchao, He,Hongchun

Source: OncoTargets and Therapy, Vol Volume 14, Pp 3051-3062 (2021)
OncoTargets and therapy

Subject Terms: ifnγ pd-l1 ctl colorectal cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, Pharmacology (medical), Oncology, Original Research, IFNγ, PD-L1, CTL, colorectal cancer, OncoTargets and Therapy

File Description: text/html

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::719e6178fe26c3b90382ed557162fbfb
https://www.dovepress.com/ifngammapd-l1-signaling-improves-the-responsiveness-of-anti-pd-1-thera-peer-reviewed-fulltext-article-OTT

17
Academic Journal
Engineered scPDL1-DM1 drug conjugate with improved in vitro analysis to target PD-L1 positive cancer cells and intracellular trafficking studies in cancer therapy

Authors: Kalim, Muhammad, Wang, Shenghao, Liang, Keying, Khan, Muhammad Saleem Iqbal, Zhan, Jinbiao

Source: Genetics and Molecular Biology. January 2019 42(4)

Subject Terms: Antibody-drug conjugate, biotherapeutics, cancer therapy, intracellular trafficking, PD-L1

File Description: text/html

Access URL: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572019000500101

Accede al texto completo
18
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Authors: Dmitry Bentsion, Virote Sriuranpong, George D. Yancopoulos, Chieh-I Chen, Miranda Gogishvili, Sue Lee, Igor Bondarenko, Mahmut Gumus, Irfan Cicin, Tamta Makharadze, Saadettin Kilickap, Bo Gao, P. Rietschel, Naiyer A. Rizvi, Kristina McGuire, Haci Mehmet Turk, Frank Seebach, Marina Nechaeva, Siyu Li, David M. Weinreich, Giuseppe Gullo, Israel Lowy, Oleg Gladkov, Semra Paydas, Ahmet Sezer, Mustafa Ozguroglu, Philip Clingan

Source: The Lancet. 397:592-604

Subject Terms: General Medicine, Medicine, business.industry, business, PD-L1, biology.protein, biology, Lung cancer, medicine.disease, Randomized controlled trial, law.invention, law, Phases of clinical research, Adverse effect, Internal medicine, medicine.medical_specialty, Chemotherapy, medicine.medical_treatment, Hazard ratio, Population, education.field_of_study, education, a multicentre, open-label, global, phase 3, randomised, controlled trial.-, Lancet (London, England), cilt.397, ss.592-604, 2021 [Sezer A., Kilickap S., Gümüş M., Bondarenko I., Özgüroğlu M., Gogishvili M., Turk H. M. , Cicin I., Bentsion D., Gladkov O., et al., -Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%]

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b83816747afb1802082cc7a5418f2da5
https://api.elsevier.com/content/article/PII:S0140673621002282?httpAccept=text/xml

19
Immune checkpoint inhibitor therapy in HIV-associated Merkel cell carcinoma: A case series of 3 patients

Authors: Kelly G. Paulson, Candice D. Church, Nora A. Alexander, Nancy S. Lee, Karl D. Lewis, Song Youn Park, Paul Nghiem, Michi M. Shinohara

Source: JAAD Case Reports, Vol 8, Iss, Pp 28-33 (2021)
JAAD Case Reports

Subject Terms: AIDS, anti-PD-(L)1 agent, HIV, immunotherapy, MCC, Merkel cell carcinoma, lcsh:Dermatology, lcsh:RL1-803, Dermatology, Cancer research, Human immunodeficiency virus (HIV), medicine.disease_cause, medicine, medicine.disease, business.industry, business, Immune checkpoint inhibitors, PD-L1, biology.protein, biology, Immunohistochemistry, Merkel cell polyomavirus, biology.organism_classification, Immunotherapy, medicine.medical_treatment, Acquired immunodeficiency syndrome (AIDS), Case Report, aMCC, advanced Merkel cell carcinoma, CR, complete response, ICI, immune checkpoint inhibitors, IHC, immunohistochemistry, MCC, Merkel cell carcinoma, MCPyV, Merkel cell polyomavirus, PD-1, anti-programmed cell death-1, PD-L1, anti-programmed death ligand-1, PET, positron emission tomography, RT, radiation treatment

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc06c2e9d001058c4c8f7e1820262c58
http://www.sciencedirect.com/science/article/pii/S2352512620308183

Search Tools: Get RSS Feed — Email this Search